NASDAQ: PEPGPepgen Inc Stock
$4.48+0.19 (+4.43%)
Updated Feb 6, 2026
PEPG Price
$4.48
Fair Value Price
$0.97
Market Cap
$307.99M
52 Week Low
$0.88
52 Week High
$7.80
P/E
-1.59x
P/B
1.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$93.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$85M
Beta
1.22
Next Earnings
Mar 19, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PEPG Overview
PepGen Inc. is developing oligonucleotide therapeutics to treat severe neuromuscular and neurologic diseases. The company's pipeline includes PGN-EDO51, PGN-EDO53, PGN-EDO45, and PGN-EDO44 to treat Duchenne Muscular Dystrophy, and PGN-EDODM1 to treat myotonic dystrophy type 1. PepGen was founded in 2018 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PEPG's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PEPG
Ranked#162 of 483
Ranked#162 of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.38 | A | |
| $165.50 | A | |
| $16.09 | A |
Be the first to know about important PEPG news, forecast changes, insider trades & much more!
PEPG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PEPG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PEPG ($4.48) is overvalued by 359.99% relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PEPG ($4.48) is not significantly undervalued (359.99%) relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PEPG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PEPG due diligence checks available for Premium users.
Valuation
PEPG fair value
Fair Value of PEPG stock based on Discounted Cash Flow (DCF)
Price
$4.48
Fair Value
$0.97
Overvalued by
359.99%
PEPG ($4.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PEPG ($4.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PEPG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PEPG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.59x
Industry
234.95x
Market
42.26x
PEPG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.89x
Industry
5.16x
PEPG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PEPG's financial health
Profit margin
Revenue
$0.0
Net Income
-$18.0M
Profit Margin
0%
PEPG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$190.1M
Liabilities
$26.9M
Debt to equity
0.17
PEPG's short-term assets ($166.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PEPG's short-term assets ($166.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PEPG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.3M
Investing
$18.9M
Financing
$108.1M
PEPG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PEPG vs Biotech Stocks
Pepgen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.